Empire Genomics is developing the first molecular diagnostic test for multiple myeloma (MM) using a novel genomic biomarker from Emory University that will allow providers to select the right treatments for the right patients based on their genetic profile.
Recent data indicate that genetic biomarkers may differentiate between patients with MM who would benefit from treatment with specific therapies, whereas others will not. A phase 2 biomarker-driven clinical trial is being launched to validate the ability of this novel technology to predict outcomes of new drugs for the treatment of MM.
“Developing a clinically validated multiple myeloma cancer theranostic assay with informative data would represent a major breakthrough in improving disease management,” said Leon Bernal-Mizrachi, MD, Assistant Professor of Hematology and Medical Oncology, Emory University School of Medicine. “It would fulfill an unmet medical need to help patients with multiple myeloma.” Anthony Johnson, CEO of Empire Genomics, added, “This is a meaningful breakthrough in the area of personalized medicine.” Empire Genomics press release, November 11, 2012
